IVAT Proposal Drafters Consider Alternatives, Faced With FDA Reservations
This article was originally published in The Gray Sheet
Executive Summary
Industry's in vitro diagnostic analytical test (IVAT) premarket proposal is unlikely to advance in its current form
You may also be interested in...
A Brewing Debate? ASR Reg Eyed As CMS Readies For Genetic Test Rule
Extending FDA's current analyte specific reagent rule to ASR kits would help address regulatory concerns about homebrew testing, diagnostic firms contend
A Brewing Debate? ASR Reg Eyed As CMS Readies For Genetic Test Rule
Extending FDA's current analyte specific reagent rule to ASR kits would help address regulatory concerns about homebrew testing, diagnostic firms contend
IVAT Proposal In Limbo As Industry Coalition Seeks Audience WIth FDA
Stakeholders are seeking clarification on agency concerns regarding industry's in vitro analytical test premarket proposal, following an Oct. 24 meeting between reps from OIVD and the IVAT industry coalition